Alexandria Hammond
Stock Analyst at B of A Securities
(2.02)
# 2,739
Out of 4,814 analysts
14
Total ratings
50%
Success rate
-8.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Upgrades: Buy | $35 → $63 | $37.65 | +67.35% | 2 | Jan 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $563.16 | +104.20% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $22.15 | +12.89% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $24.73 | +61.78% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $77.98 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $839.90 | +19.06% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $157.44 | +20.68% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $104.53 | +5.23% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $49.23 | - | 1 | Nov 15, 2024 | |
| BIIB Biogen | Initiates: Peer Perform | n/a | $118.61 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $173.00 | +18.50% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $301.73 | -50.29% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $30 | $6.07 | +394.64% | 1 | Apr 22, 2024 |
Akero Therapeutics
Jan 30, 2025
Upgrades: Buy
Price Target: $35 → $63
Current: $37.65
Upside: +67.35%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $563.16
Upside: +104.20%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $22.15
Upside: +12.89%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $24.73
Upside: +61.78%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $77.98
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $839.90
Upside: +19.06%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $157.44
Upside: +20.68%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $104.53
Upside: +5.23%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $49.23
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $118.61
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $173.00
Upside: +18.50%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $301.73
Upside: -50.29%
Apr 22, 2024
Assumes: Buy
Price Target: $30
Current: $6.07
Upside: +394.64%